MapLight Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results, Pipeline Advances and Key Milestones

Overview

MapLight Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on central nervous system (CNS) disorders, released its fourth quarter and full year 2025 financial results alongside a comprehensive business update. With a strong balance sheet and several key clinical milestones on the horizon, the company is poised for significant progress in 2026 and beyond.

Key Highlights and Potential Price-Sensitive Information

• Clinical Trial Progress:
  • ML-007C-MA (M₁/M₄ Muscarinic Agonist) for Schizophrenia:
    • Phase 2 ZEPHYR trial is expected to reach target enrollment (~300 participants) in April 2026.
    • Topline results anticipated in Q3 2026.
    • The trial is randomized, double-blind, and placebo-controlled, targeting adult inpatients with acute psychosis.
    • Primary endpoint: Change in PANSS (Positive and Negative Syndrome Scale) total score from baseline to Week 5.
    • Key secondary endpoints: PANSS-Marder positive/negative factor scores and CGI-S score changes.
  • ML-007C-MA for Alzheimer’s Disease Psychosis (ADP):
    • Received FDA Fast Track designation for treatment of hallucinations and delusions associated with ADP.
    • Phase 2 VISTA trial expected to deliver topline results in H2 2027 with ~300 participants.
  • ML-004 (5-HT_1B/1D Agonist) for Autism Spectrum Disorder (ASD):
    • Completed enrollment in IRIS Phase 2 trial (~160 adult and adolescent participants).
    • Topline results expected Q3 2026.
    • Trial focuses on improving core social communication deficits, with irritability symptoms as a key secondary endpoint.
  • ML-055 (Next-Generation M₁/M₄ Muscarinic Agonist):
    • Preclinical studies show significantly greater potency than ML-007.
    • Potential for once-daily dosing and long-acting injectable formulation.
    • Candidate nomination for IND-enabling studies expected in 2026.
• Financial Position:
  • Ended 2025 with \$453.1 million in cash, cash equivalents, and investments—expected to fund operations through 2027.
  • R&D Expenses: \$64.6 million in Q4 2025 (up from \$20.7 million Q4 2024); \$138.3 million for FY 2025 (up from \$68.5 million FY 2024). Increase primarily due to clinical trial expenses and employee-related costs, including IPO-related stock-based compensation.
  • G&A Expenses: \$18.8 million in Q4 2025 (up from \$2.1 million Q4 2024); \$30.7 million for FY 2025 (up from \$14.4 million FY 2024). Driven by employee costs, stock-based compensation, and professional fees.
  • Net Loss: \$79.5 million in Q4 2025 (vs. \$21.2 million Q4 2024); \$161.2 million for FY 2025 (vs. \$77.6 million FY 2024).
  • Balance Sheet: Total assets of \$479.5 million at year-end 2025, with total liabilities of \$21.1 million and shareholders’ equity of \$458.4 million.
• Strategic and Operational Update:
  • MapLight’s focused strategy, robust trial execution, and expansion into next-generation muscarinic agonists position it well for near-term clinical readouts and long-term pipeline growth.
  • The company has maintained strong enrollment pace in its pivotal ZEPHYR schizophrenia study and expects to hit target enrollment in April 2026.
  • Major clinical data readouts from both ZEPHYR (schizophrenia) and IRIS (autism) Phase 2 trials expected in Q3 2026—potentially transformative for shareholder value.

Details for Investors

Clinical Milestones: MapLight’s near-term pipeline is approaching several high-impact milestones:

• Two Phase 2 trial topline readouts (schizophrenia and autism) in Q3 2026. If positive, these could substantially de-risk programs and catalyze share price appreciation.
• FDA Fast Track designation for ML-007C-MA in ADP adds regulatory momentum and may accelerate development and potential commercialization.
• Expansion into next-generation muscarinic agonists (ML-055) provides additional upside and diversification, with preclinical candidate nomination expected in 2026.

Financial Strength: MapLight’s cash position of \$453.1 million and projected operational runway through 2027 reduces financing risk and supports continued clinical and preclinical development.

Risks: The company’s net loss increased substantially due to ramp-up in R&D and G&A expenses, partly related to IPO stock-based compensation. Investors should monitor future burn rates and clinical outcome risk.

Shareholder Value: Upcoming catalysts (clinical trial results, regulatory milestones, pipeline expansion) are likely to be highly price-sensitive. Positive trial outcomes or regulatory advancements could drive significant re-rating of MapLight’s valuation. Conversely, negative trial results, delays, or regulatory setbacks could impact share price.

Company Background

MapLight Therapeutics was founded by leaders in psychiatry and neuroscience to address the lack of circuit-specific pharmacotherapies for CNS disorders. Its platform aims to identify disease-linked neural circuits and develop targeted therapies.

For further information, visit www.maplightrx.com.

Forward-Looking Statements Disclaimer

This article includes forward-looking statements regarding MapLight Therapeutics’ clinical programs, financial outlook, and business strategy. Actual results may differ materially due to risks including but not limited to: clinical trial outcomes, regulatory review, operational execution, macroeconomic factors, and ability to secure future capital. Investors are encouraged to review the company’s filings with the U.S. Securities and Exchange Commission for additional risk disclosures. This article does not constitute investment advice.

View MapLight Therapeutics, Inc. Historical chart here